Curewell Capital Acquires Majority Stake in Wilmington PharmaTech

Wilmington PharmaTech (WPT), a prominent manufacturer of small molecule active pharmaceutical ingredients (API) based in the United States, has entered into a significant partnership with Curewell Capital, a private equity firm located in Los Angeles. This collaboration involves Curewell Capital acquiring a majority stake in the company, with the intention of accelerating WPT’s expansion and enhancing its domestic pharmaceutical manufacturing capabilities.

Hui-Yin “Harry” Li, Ph.D., the founder and CEO of Wilmington PharmaTech, will maintain a substantial ownership position and will continue to lead the company alongside its existing management team. This partnership is expected to provide vital growth capital, enabling WPT to expand its manufacturing footprint and improve its end-to-end API development and production services.

Founded in 2003, WPT has established itself as a reliable partner for global drug developers. The company offers a range of integrated services that encompass discovery, clinical development, and commercial-scale manufacturing. WPT operates from a 54-acre campus in Delaware, which features two advanced facilities equipped with current Good Manufacturing Practice (cGMP) and high potency API suites. Additionally, WPT has an R&D center located in Suzhou, China.

Dr. Li expressed enthusiasm about the partnership, stating, “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies. We are committed to expanding our capabilities and capacity to better serve our global biopharmaceutical partners.”

Curewell Capital partner Michael Dal Bello highlighted the scientific depth and operational excellence of Wilmington PharmaTech. He noted that the investment aligns with the increasing demand for specialized pharmaceutical manufacturing within the United States. “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity,” Dal Bello remarked.

This acquisition positions Wilmington PharmaTech to take advantage of the growing domestic and international demand for advanced API development. The partnership is set to strengthen WPT’s role as a key manufacturing partner for biopharma innovators in the U.S. and beyond.

As Wilmington PharmaTech embarks on this new chapter, the company is poised to enhance its contributions to the pharmaceutical industry, responding effectively to the evolving needs of its partners. With a strong foundation and increased resources, WPT aims to elevate its service offerings and manufacturing capabilities, ensuring it remains a trusted ally for drug developers around the globe.